These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31202428)

  • 1. Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results.
    Elmariah H; Fuchs EJ
    Semin Hematol; 2019 Jul; 56(3):183-189. PubMed ID: 31202428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
    Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.
    Munchel AT; Kasamon YL; Fuchs EJ
    Best Pract Res Clin Haematol; 2011 Sep; 24(3):359-68. PubMed ID: 21925089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.
    Luznik L; O'Donnell PV; Fuchs EJ
    Semin Oncol; 2012 Dec; 39(6):683-93. PubMed ID: 23206845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative.
    de la Fuente J; Dhedin N; Koyama T; Bernaudin F; Kuentz M; Karnik L; Socié G; Culos KA; Brodsky RA; DeBaun MR; Kassim AA
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1197-1209. PubMed ID: 30500440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Conditioning with Thiotepa in T Cell- Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors.
    Duléry R; Ménard AL; Chantepie S; El-Cheikh J; François S; Delage J; Giannotti F; Ruggeri A; Brissot E; Battipaglia G; Malard F; Belhocine R; Sestili S; Vekhoff A; Delhommeau F; Reman O; Legrand O; Labopin M; Rubio MT; Mohty M
    Biol Blood Marrow Transplant; 2018 May; 24(5):1013-1021. PubMed ID: 29337223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
    Karam E; Laporte J; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A; Solh MM
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2054-2060. PubMed ID: 31173900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.
    Kanakry CG; Bakoyannis G; Perkins SM; McCurdy SR; Vulic A; Warren EH; Daguindau E; Olmsted T; Mumaw C; Towlerton AMH; Cooke KR; O'Donnell PV; Symons HJ; Paczesny S; Luznik L
    Haematologica; 2017 May; 102(5):932-940. PubMed ID: 28126963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis.
    Metheny L; de Lima M
    Expert Rev Hematol; 2019 Jan; 12(1):47-60. PubMed ID: 30582393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies.
    Katsanis E; Sapp LN; Varner N; Koza S; Stea B; Zeng Y
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2034-2039. PubMed ID: 29908231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
    Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
    J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in HLA-haploidentical transplantations.
    Showel M; Fuchs EJ
    Best Pract Res Clin Haematol; 2015; 28(2-3):141-6. PubMed ID: 26590771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies.
    Baker M; Wang H; Rowley SD; Cai L; Pecora AL; Skarbnik A; Vesole DH; Adler-Brecher B; Kim D; Donato ML
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2047-2055. PubMed ID: 27522040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
    Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
    McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
    Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The calcineurin inhibitor and the intensity of the conditioning regimen may affect the occurrence of polyomavirus-associated hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.
    Rimondo A; Crocchiolo R; El-Cheikh J; Bramanti S; Granata A; Furst S; Sarina B; Morabito L; Devillier R; Harbi S; Mohty B; Mineri R; Faucher C; Chabannon C; Santoro A; Blaise D; Castagna L
    Bone Marrow Transplant; 2017 Jan; 52(1):135-137. PubMed ID: 27427919
    [No Abstract]   [Full Text] [Related]  

  • 18. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.
    Ebens CL; McGrath JA; Tamai K; Hovnanian A; Wagner JE; Riddle MJ; Keene DR; DeFor TE; Tryon R; Chen M; Woodley DT; Hook K; Tolar J
    Br J Dermatol; 2019 Dec; 181(6):1238-1246. PubMed ID: 30843184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.
    Bashey A; Zhang X; Sizemore CA; Manion K; Brown S; Holland HK; Morris LE; Solomon SR
    J Clin Oncol; 2013 Apr; 31(10):1310-6. PubMed ID: 23423745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.